Navigating Latency-Inducing Viral Infections: Therapeutic Targeting and Nanoparticle Utilization

Area of Science:

• Virology and Nanotechnology

Background:

• Viral latency is a critical survival mechanism for viruses such as herpesviruses, HIV, and HPV.
• Latent viruses exist in dormant states (episomal or proviral), evading host defenses and posing challenges for eradication.
• Viral integration into host DNA impacts host-pathogen dynamics and clinical outcomes, particularly in HIV infections.

Purpose of the Study:

• To review the mechanisms of viral latency and the challenges in eliminating latent viral reservoirs.
• To explore the potential of nanotechnology-based interventions for combating latent viral infections.
• To highlight advances in nanocarriers for targeted delivery of latency-reversing agents.

Main Methods:

• Review of scientific literature on viral latency mechanisms.
• Exploration of epigenetic and genetic intervention strategies.
• Analysis of nanotechnology applications, including nanoparticles and liposomes, for drug delivery, gene editing, and vaccination.

Main Results:

• Nanocarriers (nanoparticles, liposomes) show promise for precise delivery of latency-reversing agents, overcoming biological barriers and enabling sustained release.
• Nanotechnology platforms offer targeted, efficient, and multifunctional therapeutic strategies for latent viral infections.
• Advances in lipid-based, polymeric, and inorganic nanoparticles are crucial for developing novel antiviral therapies.

Conclusions:

• Combining insights into viral latency with nanotechnology advancements offers a promising path for novel therapeutic interventions.
• Nanotechnology-based strategies hold significant potential for managing persistent viral infections like neuroHIV/AIDS, herpes, and HPV.
• This approach heralds a new era in treating chronic viral diseases by targeting latent reservoirs effectively.